open access

Vol 66, No 3 (2008)
Other
Published online: 2008-03-21
Submitted: 2012-12-28
Get Citation

Original articles
Heart-type fatty acid binding protein – a reliable marker of myocardial necrosis in a heterogeneous group of patients with acute coronary syndrome without persistent ST elevation

Łukasz Figiel, Jarosław D. Kasprzak, Jan Peruga, Piotr Lipiec, Jarosław Drożdż, Maria Krzemińska Pakuła, Janusz Śmigielski
Kardiol Pol 2008;66(3):253-259.

open access

Vol 66, No 3 (2008)
Other
Published online: 2008-03-21
Submitted: 2012-12-28

Abstract

Background: Myocardial infarction (MI) is one of the most serious challenges of contemporary cardiology. Among biochemical markers, heart-type specific fatty acid binding protein (h-FABP) has a high potential as a marker for the early diagnosis of acute MI. The h-FABP is released early to the bloodstream and may be useful for both rapid confirmation and exclusion of infarction. As opposed to patients with ST segment elevation MI (STEMI), patients with unstable angina (UA)/non-ST segment elevation MI (NSTEMI) present a heterogeneous group in which the confirmation of MI often meets diagnostic difficulties. A rapid, qualitative immunoenzymatic ‘point of care’ type test, revealing h-FABP in blood, has recently been made available (CardioDetect med).
Aim: To evaluate diagnostic value of early measurements of h-FABP and other markers of necrosis (cTnT, CK-MB, CK-MB mass) in a group of 100 patients with an acute coronary syndrome (ACS) without persistent ST segment elevation (NSTE ACS).
Methods: We studied 100 consecutive patients (34 women, 66 men; mean age 61.6 years) with strong suspicion of NSTE ACS and chest pain lasting

Abstract

Background: Myocardial infarction (MI) is one of the most serious challenges of contemporary cardiology. Among biochemical markers, heart-type specific fatty acid binding protein (h-FABP) has a high potential as a marker for the early diagnosis of acute MI. The h-FABP is released early to the bloodstream and may be useful for both rapid confirmation and exclusion of infarction. As opposed to patients with ST segment elevation MI (STEMI), patients with unstable angina (UA)/non-ST segment elevation MI (NSTEMI) present a heterogeneous group in which the confirmation of MI often meets diagnostic difficulties. A rapid, qualitative immunoenzymatic ‘point of care’ type test, revealing h-FABP in blood, has recently been made available (CardioDetect med).
Aim: To evaluate diagnostic value of early measurements of h-FABP and other markers of necrosis (cTnT, CK-MB, CK-MB mass) in a group of 100 patients with an acute coronary syndrome (ACS) without persistent ST segment elevation (NSTE ACS).
Methods: We studied 100 consecutive patients (34 women, 66 men; mean age 61.6 years) with strong suspicion of NSTE ACS and chest pain lasting
Get Citation

Keywords

acute coronary syndrome; myocardial infarction; markers of necrosis

About this article
Title

Original articles
Heart-type fatty acid binding protein – a reliable marker of myocardial necrosis in a heterogeneous group of patients with acute coronary syndrome without persistent ST elevation

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 66, No 3 (2008)

Pages

253-259

Published online

2008-03-21

Bibliographic record

Kardiol Pol 2008;66(3):253-259.

Keywords

acute coronary syndrome
myocardial infarction
markers of necrosis

Authors

Łukasz Figiel
Jarosław D. Kasprzak
Jan Peruga
Piotr Lipiec
Jarosław Drożdż
Maria Krzemińska Pakuła
Janusz Śmigielski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl